What BD's 8-K filings say: 10 filings, latest Nov 5, 2026
BD filed its latest 8-K with the SEC on Nov 5, 2026. It discusses capex increase, major contract win and product launch.
Get BD's live signals in Claude or ChatGPT, or by API
What changed at BD this week? Use Autobound signals for bd.com.- Filed
- Nov 5, 2026
- Filings
- 10
- Signals
- 29
Source: Autobound Signal API · 117 signals tracked for BD · updated
8-K · latest 10
What BD's 8-K filings say
- SEC EDGAR
8-K
Filed · 4 signals
BD announced a partnership with the U.S. Government intending to invest $19 billion over several years, with $3 billion specifically directed toward domestic manufacturing expansion.
$3B
directed toward manufacturing expansion
BD launches Liverty TIPS Stent Graft in U.S. for advanced liver disease care
BD announced the U.S. launch of the BD Liverty TIPS Stent Graft, backed by six-month interim clinical data from the ARCH study.
BD eliminates Life Sciences segment following spin-off and combination with Waters
BD completed the spin-off and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, reorganizing into four distinct separately-managed segments.
Fairview Health Services deploys BD Vmax 160 Pharmacy Automation Robot in U.S.
Fairview Health Services became the first health system in the U.S.
Pharmacy Automation Robot
- SEC EDGAR
8-K
Filed · 3 signals
BDX President of Medical & BioPharma segments to retire; search for successor underway
The retirement of Michael D. Garrison, President of the Medical Essentials segment, triggers a search for a new leader.
BDX EVP Michael Garrison to retire, triggering leadership search and segment reorganization.
The BioPharma Systems segment will now report directly to the CEO, indicating increased executive oversight and potential strategic shifts.
- SEC EDGAR
8-K
Filed · 5 signals
The company is responding to an FDA Warning Letter concerning its El Paso plant, which forced a temporary halt in product shipments and implementation of new testing protocols.
BDX resumes shipment of ChloraPrep™ & PurPrep™ after voluntary ship hold due to quality concerns.
The company placed its ChloraPrep™ and PurPrep™ products on a ship hold in the U.S.
BDX addresses quality issues after FDA Warning Letter for its El Paso manufacturing facility.
The company was forced to implement additional final release testing for its ChloraPrep™ and PurPrep™ products due to an FDA Warning Letter.
BDX resumes product shipments after hold prompted by FDA Warning Letter
A voluntary ship hold on ChloraPrep™ and PurPrep™ was enacted due to an FDA Warning Letter at its El Paso manufacturing facility, indicating significant quality control and compliance challenges.
Earlier 8-K filings
Showing 10 of 29 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track BD with the Signal API
One POST /v1/companies/enrich call with bd.com returns BD 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bd.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about BD 8-K
When did BD file its latest 8-K?
What did BD disclose in its latest 8-K?
Where can I read BD's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .